Latest & greatest articles for aids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for aids

481. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.

Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. 9820261 1998 11 25 1998 11 25 2016 10 17 0098-7484 280 18 1998 Nov 11 JAMA JAMA Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. 1590-5 Peripheral neuropathy is common in persons infected (...) ) a modified double-blind design of an SAR vs control points, or (3) a double-blind design of amitriptyline vs placebo. Terry Beirn Community Programs for Clinical Research on AIDS (HIV primary care providers) in 10 US cities. Patients with HIV-associated, symptomatic, lower-extremity peripheral neuropathy. Of 250 patients enrolled, 239 were in the acupuncture comparison (125 in the factorial option and 114 in the SAR option vs control points option), and 136 patients were in the amitriptyline comparison

JAMA1998

482. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.

Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. 9791141 1998 10 29 1998 10 29 2017 02 14 0028-4793 339 18 1998 10 29 The New England journal of medicine N. Engl. J. Med. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. 1261-8 Combination antiretroviral therapy

NEJM1998

483. Complementary AIDS therapies: the good, the bad and the ugly

Complementary AIDS therapies: the good, the bad and the ugly Complementary AIDS therapies: the good, the bad and the ugly Complementary AIDS therapies: the good, the bad and the ugly Ernst E Authors' objectives To assess the published data on the use of complementary medicine by HIV-infected or AIDS patients. Searching MEDLINE was searched from 1980 to 1996 using the term 'alternative medicine'. Additional references were obtained by searching relevant journals not listed on MEDLINE, personal (...) files, files from other experts working in the field, and the bibliographies of all located articles. Study selection Study designs of evaluations included in the review Questionnaire surveys and cohort studies were considered. Specific interventions included in the review Massage, acupuncture, vitamins and herbal remedies; immunostimulation; diets; healing; imagery; bodywork; psychotherapies; homoeopathy. Participants included in the review HIV-infected and/or AIDS patients were included. Outcomes

DARE.1997

484. Effectiveness of the 40 adolescent aids-risk reduction interventions: a quantitative review

Effectiveness of the 40 adolescent aids-risk reduction interventions: a quantitative review Effectiveness of the 40 adolescent aids-risk reduction interventions: a quantitative review Effectiveness of the 40 adolescent aids-risk reduction interventions: a quantitative review Kim N, Stanton B, Li X, Dickersin K, Galbraith J Authors' objectives To review the effectiveness in adolescents of prevention interventions for AIDS, and in addition to examine the relation between intervention design (...) issues and outcome measures. Searching AIDSLINE, MEDLINE, PsycLIT, CINAHL, and Current Contents were searched for articles published between January 1983 and November 1995, using the search words terms 'AIDS', 'HIV', 'health education', 'adolescents/adolescence', 'prevention', 'intervention' and 'evaluation'. Additional studies were located by searching all articles cited in the retrieved studies, and by handsearching 11 journals (from 1983 to 1995; publication list given in authors' text

DARE.1997

485. Cost-effectiveness of an HIV/AIDS prevention intervention for gay men

Cost-effectiveness of an HIV/AIDS prevention intervention for gay men Cost-effectiveness of an HIV/AIDS prevention intervention for gay men Cost-effectiveness of an HIV/AIDS prevention intervention for gay men Holtgrave D R, Kelly J A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology An HIV/AIDS prevention intervention for gay men. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population consisted of gay men who had engaged in behaviour with a high risk of HIV infection. Setting The setting was a medical school outreach programme. The economic study was carried out in the USA. Dates to which data relate Effectiveness data were collected from studies published

NHS Economic Evaluation Database.1997

486. Assessment of computer-aided assistive technology: analysis of outcomes and costs

Assessment of computer-aided assistive technology: analysis of outcomes and costs Assessment of computer-aided assistive technology: analysis of outcomes and costs Assessment of computer-aided assistive technology: analysis of outcomes and costs Hass U, Andersson A, Brodin H, Persson J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Computer-Aided Assistive Technology (CAAT) for individuals with communication disabilities. Type of intervention Treatment and rehabilitation. Economic study type Cost-effectiveness analysis. Study population Male and female individuals with communication disabilities who were referred to the regional CAAT centres. Setting CAAT centres. The economic study was carried out in Uppsala, Sweden. Dates

NHS Economic Evaluation Database.1997

487. The cost-effectiveness of fluconzaole prophylaxis against primary systemic fungal infections in AIDS patients

The cost-effectiveness of fluconzaole prophylaxis against primary systemic fungal infections in AIDS patients The cost-effectiveness of fluconzaole prophylaxis against primary systemic fungal infections in AIDS patients The cost-effectiveness of fluconzaole prophylaxis against primary systemic fungal infections in AIDS patients Scharfstein J A, Paltiel A D, Freedberg K A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Fluconazole prophylaxis for primary systemic fungal infection in AIDS patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population A hypothetical cohort of AIDS patients. No further details were given. Setting Hospital. The economic study was carried out

NHS Economic Evaluation Database.1997

488. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing

Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing Rose D N, Sacks H S Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Strategies to prevent cytomegalovirus (CMV) disease in patients with AIDS: oral ganciclovir (GCV) (1g three times daily) and CMV polymerase chain reaction testing (every three months). Type of intervention Secondary prevention

NHS Economic Evaluation Database.1997

489. Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis

Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis Freedberg K A, Cohen C J, Barber T W Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prophylaxis for disseminated Mycobacterium avium Complex (MAC) infection in patients with AIDS: rifabutin (300 mg/day), azithromycin (1200mg/week) and clarithromycin (500 mg twice per day) were compared with no prophylaxis. Type of intervention Treatment; secondary

NHS Economic Evaluation Database.1997

490. Improved AIDS surveillance through laboratory-initiated CD4 cell count reporting

Improved AIDS surveillance through laboratory-initiated CD4 cell count reporting Improved AIDS surveillance through laboratory-initiated CD4 cell count reporting Improved AIDS surveillance through laboratory-initiated CD4 cell count reporting McAnulty J M, Modesitt S K, Yusem S H, Hyer C J, Fleming D W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Laboratory-initiated CD4 reporting (LICR), for the surveillance of AIDS. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis Study population Persons infected with HIV. Setting The economic study was carried out in Oregon, USA. Dates to which data relate Resource use and effectiveness data were collected from May 1993 to April 1994. The price year

NHS Economic Evaluation Database.1997

491. Drug treatment of AIDS and HIV: summary

Drug treatment of AIDS and HIV: summary Drug treatment of AIDS and HIV: summary Drug treatment of AIDS and HIV: summary Scottish Health Purchasing Information Centre Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made for the HTA database. Citation Scottish Health Purchasing Information (...) Centre. Drug treatment of AIDS and HIV: summary. Aberdeen: Scottish Health Purchasing Information Centre (SHPIC) 1997 Authors' objectives This report addresses the following questions: 1. What is the best choice of treatment for HIV? 2. Should treatment be started early or late in HIV infection? 3. What is best treatment for cytomegalovirus retinitis? 4. What is the best prophylactic treatment for pneumocystis carinii? 5. What is the best treatment in special situations eg a) maternal transmission b

Health Technology Assessment (HTA) Database.1997

492. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. 9287227 1997 09 11 1997 09 11 2013 11 21 0028-4793 337 11 1997 Sep 11 The New England journal of medicine N. Engl. J. Med. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic (...) millimeter or less. AIDS Clinical Trials Group 320 Study Team. 725-33 The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine with treatment with the two nucleosides alone in HIV-infected adults previously treated with zidovudine. A total of 1156 patients not previously treated with lamivudine

NEJM1997

493. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. 9154767 1997 05 22 1997 05 22 2013 11 21 0028-4793 336 21 1997 May 22 The New England journal of medicine N. Engl. J. Med. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical (...) Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. United States N Engl J Med 0255562 0028-4793 0 Receptors, Tumor Necrosis Factor 0 Tumor Necrosis Factor-alpha 4Z8R6ORS6L Thalidomide AIM IM X N Engl J Med. 1997 Oct 9;337(15):1086-7 9324641 Acquired Immunodeficiency Syndrome complications Adult Double-Blind Method Female HIV-1 drug effects isolation & purification Humans Male Quality of Life Receptors, Tumor Necrosis Factor blood Stomatitis, Aphthous drug

NEJM1997

494. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. 9171066 1997 06 05 1997 06 05 2015 11 19 0028-4793 336 23 1997 Jun 05 The New England journal of medicine N. Engl. J. Med. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National (...) Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. 1641-8 Reduced doses of cytotoxic chemotherapy or standard-dose therapy plus a myeloid colony-stimulating factor decreases hematologic toxicity and its complications in patients with non-Hodgkin's lymphoma associated with infection with the human immunodeficiency virus (HIV). However, the effect of reducing the doses of cytotoxic chemotherapeutic agents on clinical outcome is not known. We randomly assigned 198 HIV-seropositive

NEJM1997

495. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.

Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. 9182213 1997 06 12 1997 06 12 2013 11 21 0028-4793 336 24 1997 Jun 12 The New England journal of medicine N. Engl. J. Med. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. 1704-12 Zidovudine has been the drug of choice for the initial treatment

NEJM1997

496. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. 9203426 1997 07 08 1997 07 08 2013 11 21 0028-4793 337 1 1997 Jul 03 The New England journal of medicine N. Engl. J. Med. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS (...) Clinical Trials Group. 15-21 Treatment with low-dose amphotericin B (0.4 mg per kilogram of body weight per day) or oral azole therapy in patients with the acquired immunodeficiency syndrome (AIDS) and cryptococcal meningitis has been associated with high mortality and low rates of cerebrospinal fluid sterilization. In a double-blind multicenter trial we randomly assigned patients with a first episode of AIDS-associated cryptococcal meningitis to treatment with higher-dose amphotericin B (0.7 mg per

NEJM1997

497. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS.

A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. 9233868 1997 07 31 1997 07 31 2013 11 21 0028-4793 337 5 1997 Jul 31 The New England journal of medicine N. Engl. J. Med. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs (...) for Clinical Research on AIDS. 315-20 Patients with human immunodeficiency virus (HIV) infection and latent tuberculosis are at substantial risk for the development of active tuberculosis. As a public health measure, prophylactic treatment with isoniazid has been suggested for HIV-infected persons who have anergy and are in groups with a high prevalence of tuberculosis. We conducted a multicenter, randomized, double-blind, placebo-controlled trial of six months of prophylactic isoniazid treatment in HIV

NEJM1997

498. The health effects of worksite HIV/AIDS interventions: a review of the research literature

The health effects of worksite HIV/AIDS interventions: a review of the research literature The health effects of worksite HIV/AIDS interventions: a review of the research literature The health effects of worksite HIV/AIDS interventions: a review of the research literature Wilson M G, Jorgensen C, Cole G Authors' objectives To examine the individual and organisational effects of HIV/AIDS interventions conducted in worksites. Searching The Centers for Disease Control and Prevention (CDCP (...) Information Service, and the Substance Abuse Information databases. Areas searched included HIV/AIDS, and multicomponent programmes. The CDC also manually searched health promotion journals to identify articles missed by the computer search, particularly those published after the search was conducted and those found in journals not included in the databases. The CDC search also checked references of identified articles for additional studies. In addition, the authors of this review manually searched new

DARE.1996

499. Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention

Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention Holtgrave D R, Kelly J A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) that generalisation of the results should be made only to organisations already delivering some type of "behaviourally based" HIV prevention programme (no capital or start-up costs were included). Source of funding Supported in part by grants RO1-MH55440 and P30-MH52776 from the National Institute of Mental Health. Bibliographic details Holtgrave D R, Kelly J A. Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention. American Journal of Public Health 1996; 86(10

NHS Economic Evaluation Database.1996

500. An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients

An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients Sullivan S D, Mozaffari E (...) , Johnson E S, Wolitz R, Follansbee S E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Pharmacologic agents (intravenous (IV) and oral ganciclovir) for treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. Type of

NHS Economic Evaluation Database.1996